BAX
27
-2
AA
38
-2
GS
75
-4
DOW
30
2
NKE
33
2
MRO
46
3
SYY
47
-2
PCG
99
2
HSY
43
3
EMC
53
-3
FTI
78
-3
SRE
66
-3
WFC
80
-2
DOV
73
4
PDCO
30
-6
COF
63
-4
LNC
45
-4
EXR
59
4
LOW
58
2
AVY
53
2
BAX
27
-2
AA
38
-2
GS
75
-4
DOW
30
2
NKE
33
2
MRO
46
3
SYY
47
-2
PCG
99
2
HSY
43
3
EMC
53
-3
FTI
78
-3
SRE
66
-3
WFC
80
-2
DOV
73
4
PDCO
30
-6
COF
63
-4
LNC
45
-4
EXR
59
4
LOW
58
2
AVY
53
2
Financhill
Back

Seres Therapeutics 10K Form

Sell
25

MCRB
Seres Therapeutics

Last Price:
0.58
Seasonality Move:
-13.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MCRB News And Ratings

See the #1 stock for the next 7 days that we like better than MCRB

MCRB Financial Statistics

Sales & Book Value

Annual Sales: $126.33M
Cash Flow: $-39.91M
Price / Cash Flow: 0
Annual Sales: $-0.57
Price / Book: 0

Profitability

EPS (TTM): -1.18000
Net Income (TTM): $-162.11M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Seres Therapeutics Earnings Forecast

Key Seres Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for MCRB have been equal to 69.46% of Gross Profit Margin.
  • The Research & Development expenses have been 115.46% of Revenue.
  • The Interest Expense is -11.59% of Operating Income.
  • The Net Earning history of MCRB is -90.02% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Seres Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MCRB
CUSIP: 81750R
Website: serestherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MCRB Technical Analysis vs Fundamental Analysis

Sell
25
Seres Therapeutics (MCRB) is a Sell

Is Seres Therapeutics a Buy or a Sell?